In a report released today, Marc Frahm from Cowen & Co. reiterated a Buy rating on Allogene Therapeutics (ALLO). The company’s shares closed last Monday at $26.44.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of 13.6% and a 42.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Black Diamond Therapeutics, and Adaptimmune Therapeutics.
Currently, the analyst consensus on Allogene Therapeutics is a Moderate Buy with an average price target of $36.33, which is a 42.4% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Allogene Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $50.74 million. In comparison, last year the company had a GAAP net loss of $30.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
